Scenarios that move NVO
Novo Nordisk A/S Common Stock
Scenarios that move NVO: 16 analyses, 6 positive, 10 negative.
- · Ascendis Pharma receives positive CHMP opinion for TransCon CNP — ▼ · impact -8 · confidence low · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▼ · impact -58 · confidence high · horizon quarters
- · Hims & Hers faces securities fraud class action after FTC lawsuit — ▲ · impact +35 · confidence medium · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▼ · impact -55 · confidence high · horizon immediate
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▲ · impact +88 · confidence high · horizon immediate
- · Lilly reports strong weight loss results for new drug — ▼ · impact -82 · confidence medium · horizon immediate
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▲ · impact +80 · confidence high · horizon immediate
- · Beta Bionics stock plunges 37% after safety issues emerge — ▲ · impact +8 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▲ · impact +41 · confidence medium · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▼ · impact -81 · confidence medium · horizon weeks
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -60 · confidence low · horizon quarters
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▼ · impact -54 · confidence medium · horizon weeks
- · Beta Bionics prices public offering of stock and warrants — ▼ · impact -6 · confidence low · horizon quarters
- · Ascendis announces planned $400 million share repurchase program — ▼ · impact -18 · confidence medium · horizon quarters
- · Amgen shares fall after Novartis' Pelacarsen misses Phase III goal — ▲ · impact +15 · confidence low · horizon quarters
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▼ · confidence medium